Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/43807
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorBETTAMPADI, Deepti-
dc.contributor.authorSIRAK, Bradley A.-
dc.contributor.authorABRAHAMSEN, Martha E.-
dc.contributor.authorREICH, Richard R.-
dc.contributor.authorVILLA, Luisa L.-
dc.contributor.authorPONCE, Eduardo Lazcano-
dc.contributor.authorGIULIANO, Anna R.-
dc.date.accessioned2021-12-16T14:18:43Z-
dc.date.available2021-12-16T14:18:43Z-
dc.date.issued2021-
dc.identifier.citationCLINICAL INFECTIOUS DISEASES, v.73, n.9, p.E3227-E3234, 2021-
dc.identifier.issn1058-4838-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/43807-
dc.description.abstractBackground. Human papillomavirus (HPV)-attributable oropharyngeal cancer (HPV-OPC) incidence is increasing in many high-income countries among men. Factors associated with oral HPV persistence, the precursor of HPV-OPC, are unknown. Data from the HPV Infection in Men (HIM) Study, which followed participants >7 years, were utilized to examine rates of persistence and associated factors. Methods. Oral gargle samples from 3095 HIM study participants were HPV genotyped using the SPF 10 PCR-DEIA-LiPA 25 assay (DDL Diagnostic Laboratory). Oral HPV persistence for individual and grouped high-risk HPV types among 184 men positive for any high-risk HPV at their oral baseline visit was assessed at 6-month intervals. Factors associated with grouped high-risk HPV/HPV16 persistence were examined using logistic regression. Kaplan-Meier curves were constructed to examine median time to HPV clearance overall, and by selected risk factors. Results. Among the 7 HPV vaccine types, HPV33 had the longest median duration (7.6 months) followed by HPV16 and HPV45 (6.4 months). 10-30% of oral high-risk HPV infections persisted >= 24 months. Six months' persistence of oral high-risk HPV infections was positively associated with age and gingivitis and negatively with lifetime number of sexual partners, while 12 months' persistence was only inversely associated with lifetime number of sexual partners. Oral HPV16 persistence was positively associated with baseline HPV16 L1 antibody status. Conclusions. Eighteen percent of HPV16 infections persisted beyond 24 months, potentially conferring higher risk of HPV-OPC among these men. Older age appears to be an important factor associated with oral high-risk HPV persistence. More studies among healthy men are required to understand the progression of oral HPV infection to HPV-OPC.eng
dc.description.sponsorshipNational Cancer Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA214588, P30-CA076292]-
dc.description.sponsorshipNational Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA-
dc.language.isoeng-
dc.publisherOXFORD UNIV PRESS INCeng
dc.relation.ispartofClinical Infectious Diseases-
dc.rightsrestrictedAccesseng
dc.subjectoral HPVeng
dc.subjectHPV persistenceeng
dc.subjectoropharyngeal cancereng
dc.subjectHIM studyeng
dc.subjectoral HPV clearanceeng
dc.subject.otherprevalenceeng
dc.subject.otherl1eng
dc.titleFactors Associated With Persistence and Clearance of High-Risk Oral Human Papillomavirus (HPV) Among Participants in the HPV Infection in Men (HIM) Studyeng
dc.typearticleeng
dc.rights.holderCopyright OXFORD UNIV PRESS INCeng
dc.identifier.doi10.1093/cid/ciaa1701-
dc.identifier.pmid33173937-
dc.subject.wosImmunologyeng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosMicrobiologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalBETTAMPADI, Deepti:H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA; H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA-
hcfmusp.author.externalSIRAK, Bradley A.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA-
hcfmusp.author.externalABRAHAMSEN, Martha E.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA-
hcfmusp.author.externalREICH, Richard R.:H Lee Moffitt Canc Ctr & Res Inst, Biostat & Bioinformat, Tampa, FL USA-
hcfmusp.author.externalPONCE, Eduardo Lazcano:Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, Mexico-
hcfmusp.author.externalGIULIANO, Anna R.:H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA; H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA-
hcfmusp.description.beginpageE3227-
hcfmusp.description.endpageE3234-
hcfmusp.description.issue9-
hcfmusp.description.volume73-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000753398700179-
hcfmusp.origem.id2-s2.0-85120421321-
hcfmusp.publisher.cityCARYeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceBeachler DC, 2015, SEX TRANSM DIS, V42, P93, DOI 10.1097/OLQ.0000000000000236eng
hcfmusp.relation.referenceBettampadi D, 2020, PAPILLOMAVIRUS RES, V9, DOI 10.1016/j.pvr.2020.100199eng
hcfmusp.relation.referenceCampbell CMP, 2016, J INFECT DIS, V214, P45, DOI 10.1093/infdis/jiw083eng
hcfmusp.relation.referenceChaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596eng
hcfmusp.relation.referenceD'Souza G, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa047eng
hcfmusp.relation.referenceFrisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500eng
hcfmusp.relation.referenceGillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101eng
hcfmusp.relation.referenceGiuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151eng
hcfmusp.relation.referenceKero K, 2014, EUR J CLIN MICROBIOL, V33, P123, DOI 10.1007/s10096-013-1938-1eng
hcfmusp.relation.referenceKleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-Xeng
hcfmusp.relation.referenceKreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682eng
hcfmusp.relation.referenceLowy DR, 2015, LANCET ONCOL, V16, pE226, DOI 10.1016/S1470-2045(15)70075-6eng
hcfmusp.relation.referenceNasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339eng
hcfmusp.relation.referenceCampbell CMP, 2015, CANCER PREV RES, V8, P190, DOI 10.1158/1940-6207.CAPR-14-0296eng
hcfmusp.relation.referenceTezal Mine, 2012, Int J Otolaryngol, V2012, P575242, DOI 10.1155/2012/575242eng
hcfmusp.relation.referenceTezal M, 2009, ARCH OTOLARYNGOL, V135, P391, DOI 10.1001/archoto.2009.6eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1537-6591-
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-06-09-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental


Files in This Item:
File Description SizeFormat 
art_BETTAMPADI_Factors_Associated_With_Persistence_and_Clearance_of_HighRisk_2021.PDF
  Restricted Access
publishedVersion (English)1.81 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.